Advertisement
UK markets open in 4 hours 34 minutes

  • NIKKEI 225

    36,900.28
    -1,179.42 (-3.10%)
     

  • HANG SENG

    16,188.09
    -197.78 (-1.21%)
     

  • CRUDE OIL

    85.68
    +2.95 (+3.57%)
     

  • GOLD FUTURES

    2,427.40
    +29.40 (+1.23%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    48,642.47
    -980.02 (-1.97%)
     

  • CMC Crypto 200

    1,256.89
    +371.35 (+39.50%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

AstraZeneca gets FDA priority review for experimental breast cancer drug

Reuters - UK Focus

Oct 17 (Reuters) - Drugmaker AstraZeneca Plc said on Thursday its experimental breast cancer treatment will get a speedy review by the U.S. Food and Drug Administration, with a decision by the health regulator expected in the second quarter of next year.

The British company in March agreed to pay up to $6.9 billion to work with Japan's Daiichi Sankyo Co Ltd on the treatment, trastuzumab deruxtecan or also known as DS-8201, in a direct challenge to the world's biggest cancer drug maker Roche Holding AG.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)